Transferring technology in high-burden countries

This unique approach not only allows patients to access medicines at lower prices, but also supports local economies and the manufacturing of high-quality medicines. Lilly supplies manufacturing know-how, financial assistance to purchase manufacturing equipment, and training on Good Manufacturing Practices, which raises the overall standards of safety for the production of these medicines. Lilly has negotiated agreements with the companies participating in the technology transfer, including how much may be charged for products to be used in treatment programs sponsored by the World Health Organization (WHO) and other donor organizations.

Meanwhile, Lilly continues to supply both medicines at concessionary prices to WHO-approved DOTS programs (Directly Observed Treatment, Short-course) for MDR-TB. Under DOTS, supervisors observe the patients while they are taking their medications for the duration of their treatment. These medicines are supplied through the WHO’s Global Drug Facility. Lilly has been shipping these medicines through the WHO DOTS program to patients in over 40 countries.